Latest news with #OPG
Cision Canada
7 days ago
- Business
- Cision Canada
AtkinsRéalis signs new execution contract for Darlington Small Modular Reactor Project Français
MONTREAL, May 28, 2025 /CNW/ - Candu Energy Inc., an AtkinsRéalis company [AtkinsRéalis Group Inc.] (TSX: ATRL), has been awarded a $450 million execution contract by Ontario Power Generation (OPG), for the first of four planned small modular reactor (SMR) units at the Darlington New Nuclear Project. The 300-megawatt BWRX-300 small modular reactor being delivered for OPG in Durham Region, east of Toronto, will supply enough power for 300,000 homes. 1 AtkinsRéalis is providing OPG with expertise for the engineering of the SMR. This includes project management, licensing, engineering, design, procurement, construction support and commissioning, as well as digital delivery capabilities in both the nuclear island and balance of plant scopes for the project. "As a world-class engineering services and nuclear organization, we are advocates for the role of SMRs in the energy mix to create stable, affordable, and reliable power grids," said Ian L. Edwards, President and Chief Executive Officer, AtkinsRéalis. "Our involvement in the G7's first grid-scale SMR and Canada's first nuclear new build in roughly 30 years reaffirms our leading position in the global nuclear energy market, for both large and small reactor technologies. Our trusted relationship with OPG supporting hydropower assets and refurbishing CANDU reactors at Darlington and Pickering will support this project's successful completion by 2030." AtkinsRéalis has been the architect-engineer on the Darlington New Nuclear Project alliance team since 2023. The Company is working alongside GE Vernova Hitachi Nuclear Energy and Aecon Kiewit Nuclear Partners. The site preparation work undertaken under an earlier validation phase contract has been completed on time and on budget. The Canadian Nuclear Safety Commission has issued a license to construct the SMR, and the Ontario government has also given its final approval for construction of the first of four planned units at the site. "AtkinsRéalis is a long-time trusted partner to OPG, including on the on-time, on budget Darlington Refurbishment Project," said Nicolle Butcher, OPG President and CEO. "We will draw on our shared experience for similar success as we build the first small modular reactor in the G7 at the Darlington New Nuclear Project site." "Ontario's power demand is expected to surge by 75% by 2050 2 and we'll need all sources of cleaner power to meet the need, including large and small nuclear reactor technology," said Joe St. Julian, President, Nuclear, AtkinsRéalis. "Together with our alliance partners, we will ensure Canada continues to lead the G7 in advancing the use of SMR technology, as AtkinsRéalis also continues to support international SMR projects in the UK, US, and Poland." About AtkinsRéalis Created by the integration of long-standing organizations dating back to 1911, AtkinsRéalis is a world-class engineering services and nuclear company dedicated to engineering a better future for our planet and its people. We create sustainable solutions that connect people, data and technology to transform the world's infrastructure and energy systems. We deploy global capabilities locally to our clients and deliver unique end-to-end services across the whole life cycle of an asset including consulting, advisory & environmental services, intelligent networks & cybersecurity, design & engineering, procurement, project & construction management, operations & maintenance, decommissioning and capital. The breadth and depth of our capabilities are delivered to clients in strategic sectors such as Engineering Services, Nuclear and Capital. News and information are available at or follow us LinkedIn. About AtkinsRéalis' Nuclear Sector AtkinsRéalis has over 70 years of global nuclear expertise, delivering nuclear technology products and full-service solutions to nuclear utilities around the world. AtkinsRéalis is the steward of CANDU® nuclear technology, operating on four continents, and provides advisory and engineering services to other nuclear developers. With an innovative technology portfolio, including access to over 500 patented solutions, AtkinsRéalis solves technically complex challenges across the whole nuclear lifecycle from design and new build through asset management and from life extension and late life management through decommissioning and waste management. AtkinsRéalis operates and manages government nuclear research sites, transforming ageing infrastructure and safely managing legacy nuclear waste. AtkinsRéalis' CANDU technology also allows for the co-production of medical radioisotopes for cancer detection and treatment. The company also supports cancer treatment through its partnership with TerraPower to extract isotopes from legacy nuclear material. Learn more on our Nuclear market page. Forward-Looking Statements References in this press release to the "Company", "AtkinsRéalis", "we", us" and "our" mean, as the context may require, AtkinsRéalis Group Inc. or all or some of its subsidiaries or joint arrangements or associates. Statements made in this press release that describe the Company's expectations or strategies constitute "forward-looking statements", which can be identified by the use of the conditional or forward-looking terminology such as "estimates", "expects", "forecasts", "intends", "may", "objective", "plans", "projects", "should", "will", "likely", or other variations thereon. Forward-looking statements also include any other statements that do not refer to historical facts. The Company cautions that, by their nature, forward-looking statements involve risks and uncertainties, and that its actual actions or results could differ materially from those expressed or implied in such forward-looking statements. Forward-looking statements are presented for the purpose of assisting investors and others in understanding certain key elements of the Company's current objectives, strategic priorities, expectations and plans, and in obtaining a better understanding of the Company's business and anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. Forward-looking statements made in this press release are based on a number of assumptions believed by the Company to be reasonable as at the date hereof. The assumptions are set out throughout the Company's 2024 annual management disclosure & analysis ("2024 MD&A") (particularly in the sections entitled "Critical Accounting Judgments and Key Sources of Estimation Uncertainty" and "How We Analyze and Report our Results") filed with the securities regulatory authorities in Canada, available on SEDAR+ at and on the Company's website at under the "Investors" section. If these assumptions are inaccurate, the Company's actual results could differ materially from those expressed or implied in such forward-looking statements. In addition, important risk factors could cause the Company's assumptions and estimates to be inaccurate and actual results or events to differ materially from those expressed in or implied by these forward-looking statements. Those risks are identified in the 2024 MD&A (particularly in the section entitled "Risk and Uncertainties"), as may be updated from time to time in the Company's interim quarterly MD&A, are not exhaustive. The forward-looking statements herein reflect the Company's expectations as at the date of this press release and are subject to change after this date. The Company does not undertake to update publicly or to revise any such forward-looking statements whether as a result of new information, future events or otherwise, unless required by applicable legislation or regulation. The forward-looking information and statements contained herein are expressly qualified in their entirety by this cautionary statement.
Associated Press
7 days ago
- Business
- Associated Press
AtkinsRéalis signs new execution contract for Darlington Small Modular Reactor Project
MONTREAL, May 28, 2025 /CNW/ - Candu Energy Inc., an AtkinsRéalis company [AtkinsRéalis Group Inc.] (TSX: ATRL), has been awarded a $450 million execution contract by Ontario Power Generation (OPG), for the first of four planned small modular reactor (SMR) units at the Darlington New Nuclear Project. The 300-megawatt BWRX-300 small modular reactor being delivered for OPG in Durham Region, east of Toronto, will supply enough power for 300,000 homes.1 AtkinsRéalis is providing OPG with expertise for the engineering of the SMR. This includes project management, licensing, engineering, design, procurement, construction support and commissioning, as well as digital delivery capabilities in both the nuclear island and balance of plant scopes for the project. 'As a world-class engineering services and nuclear organization, we are advocates for the role of SMRs in the energy mix to create stable, affordable, and reliable power grids,' said Ian L. Edwards, President and Chief Executive Officer, AtkinsRéalis. 'Our involvement in the G7's first grid-scale SMR and Canada's first nuclear new build in roughly 30 years reaffirms our leading position in the global nuclear energy market, for both large and small reactor technologies. Our trusted relationship with OPG supporting hydropower assets and refurbishing CANDU reactors at Darlington and Pickering will support this project's successful completion by 2030.' AtkinsRéalis has been the architect-engineer on the Darlington New Nuclear Project alliance team since 2023. The Company is working alongside GE Vernova Hitachi Nuclear Energy and Aecon Kiewit Nuclear Partners. The site preparation work undertaken under an earlier validation phase contract has been completed on time and on budget. The Canadian Nuclear Safety Commission has issued a license to construct the SMR, and the Ontario government has also given its final approval for construction of the first of four planned units at the site. 'AtkinsRéalis is a long-time trusted partner to OPG, including on the on-time, on budget Darlington Refurbishment Project,' said Nicolle Butcher, OPG President and CEO. 'We will draw on our shared experience for similar success as we build the first small modular reactor in the G7 at the Darlington New Nuclear Project site.' 'Ontario's power demand is expected to surge by 75% by 20502 and we'll need all sources of cleaner power to meet the need, including large and small nuclear reactor technology,' said Joe St. Julian, President, Nuclear, AtkinsRéalis. 'Together with our alliance partners, we will ensure Canada continues to lead the G7 in advancing the use of SMR technology, as AtkinsRéalis also continues to support international SMR projects in the UK, US, and Poland.' About AtkinsRéalis Created by the integration of long-standing organizations dating back to 1911, AtkinsRéalis is a world-class engineering services and nuclear company dedicated to engineering a better future for our planet and its people. We create sustainable solutions that connect people, data and technology to transform the world's infrastructure and energy systems. We deploy global capabilities locally to our clients and deliver unique end-to-end services across the whole life cycle of an asset including consulting, advisory & environmental services, intelligent networks & cybersecurity, design & engineering, procurement, project & construction management, operations & maintenance, decommissioning and capital. The breadth and depth of our capabilities are delivered to clients in strategic sectors such as Engineering Services, Nuclear and Capital. News and information are available at or follow us LinkedIn. About AtkinsRéalis' Nuclear Sector AtkinsRéalis has over 70 years of global nuclear expertise, delivering nuclear technology products and full-service solutions to nuclear utilities around the world. AtkinsRéalis is the steward of CANDU® nuclear technology, operating on four continents, and provides advisory and engineering services to other nuclear developers. With an innovative technology portfolio, including access to over 500 patented solutions, AtkinsRéalis solves technically complex challenges across the whole nuclear lifecycle from design and new build through asset management and from life extension and late life management through decommissioning and waste management. AtkinsRéalis operates and manages government nuclear research sites, transforming ageing infrastructure and safely managing legacy nuclear waste. AtkinsRéalis' CANDU technology also allows for the co-production of medical radioisotopes for cancer detection and treatment. The company also supports cancer treatment through its partnership with TerraPower to extract isotopes from legacy nuclear material. Learn more on our Nuclear market page. Forward-Looking Statements References in this press release to the 'Company', 'AtkinsRéalis', 'we', us' and 'our' mean, as the context may require, AtkinsRéalis Group Inc. or all or some of its subsidiaries or joint arrangements or associates. Statements made in this press release that describe the Company's expectations or strategies constitute 'forward-looking statements', which can be identified by the use of the conditional or forward-looking terminology such as 'estimates', 'expects', 'forecasts', 'intends', 'may', 'objective', 'plans', 'projects', 'should', 'will', 'likely', or other variations thereon. Forward-looking statements also include any other statements that do not refer to historical facts. The Company cautions that, by their nature, forward-looking statements involve risks and uncertainties, and that its actual actions or results could differ materially from those expressed or implied in such forward-looking statements. Forward-looking statements are presented for the purpose of assisting investors and others in understanding certain key elements of the Company's current objectives, strategic priorities, expectations and plans, and in obtaining a better understanding of the Company's business and anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. Forward-looking statements made in this press release are based on a number of assumptions believed by the Company to be reasonable as at the date hereof. The assumptions are set out throughout the Company's 2024 annual management disclosure & analysis ('2024 MD&A') (particularly in the sections entitled 'Critical Accounting Judgments and Key Sources of Estimation Uncertainty' and 'How We Analyze and Report our Results') filed with the securities regulatory authorities in Canada, available on SEDAR+ at and on the Company's website at under the 'Investors' section. If these assumptions are inaccurate, the Company's actual results could differ materially from those expressed or implied in such forward-looking statements. In addition, important risk factors could cause the Company's assumptions and estimates to be inaccurate and actual results or events to differ materially from those expressed in or implied by these forward-looking statements. Those risks are identified in the 2024 MD&A (particularly in the section entitled 'Risk and Uncertainties'), as may be updated from time to time in the Company's interim quarterly MD&A, are not exhaustive. The forward-looking statements herein reflect the Company's expectations as at the date of this press release and are subject to change after this date. The Company does not undertake to update publicly or to revise any such forward-looking statements whether as a result of new information, future events or otherwise, unless required by applicable legislation or regulation. The forward-looking information and statements contained herein are expressly qualified in their entirety by this cautionary statement. __________________ SOURCE AtkinsRéalis
Yahoo
7 days ago
- Business
- Yahoo
AtkinsRéalis signs new execution contract for Darlington Small Modular Reactor Project
MONTREAL, May 28, 2025 /CNW/ - Candu Energy Inc., an AtkinsRéalis company [AtkinsRéalis Group Inc.] (TSX: ATRL), has been awarded a $450 million execution contract by Ontario Power Generation (OPG), for the first of four planned small modular reactor (SMR) units at the Darlington New Nuclear Project. The 300-megawatt BWRX-300 small modular reactor being delivered for OPG in Durham Region, east of Toronto, will supply enough power for 300,000 homes.1 AtkinsRéalis is providing OPG with expertise for the engineering of the SMR. This includes project management, licensing, engineering, design, procurement, construction support and commissioning, as well as digital delivery capabilities in both the nuclear island and balance of plant scopes for the project. "As a world-class engineering services and nuclear organization, we are advocates for the role of SMRs in the energy mix to create stable, affordable, and reliable power grids," said Ian L. Edwards, President and Chief Executive Officer, AtkinsRéalis. "Our involvement in the G7's first grid-scale SMR and Canada's first nuclear new build in roughly 30 years reaffirms our leading position in the global nuclear energy market, for both large and small reactor technologies. Our trusted relationship with OPG supporting hydropower assets and refurbishing CANDU reactors at Darlington and Pickering will support this project's successful completion by 2030." AtkinsRéalis has been the architect-engineer on the Darlington New Nuclear Project alliance team since 2023. The Company is working alongside GE Vernova Hitachi Nuclear Energy and Aecon Kiewit Nuclear Partners. The site preparation work undertaken under an earlier validation phase contract has been completed on time and on budget. The Canadian Nuclear Safety Commission has issued a license to construct the SMR, and the Ontario government has also given its final approval for construction of the first of four planned units at the site. "AtkinsRéalis is a long-time trusted partner to OPG, including on the on-time, on budget Darlington Refurbishment Project," said Nicolle Butcher, OPG President and CEO. "We will draw on our shared experience for similar success as we build the first small modular reactor in the G7 at the Darlington New Nuclear Project site." "Ontario's power demand is expected to surge by 75% by 20502 and we'll need all sources of cleaner power to meet the need, including large and small nuclear reactor technology," said Joe St. Julian, President, Nuclear, AtkinsRéalis. "Together with our alliance partners, we will ensure Canada continues to lead the G7 in advancing the use of SMR technology, as AtkinsRéalis also continues to support international SMR projects in the UK, US, and Poland." About AtkinsRéalis Created by the integration of long-standing organizations dating back to 1911, AtkinsRéalis is a world-class engineering services and nuclear company dedicated to engineering a better future for our planet and its people. We create sustainable solutions that connect people, data and technology to transform the world's infrastructure and energy systems. We deploy global capabilities locally to our clients and deliver unique end-to-end services across the whole life cycle of an asset including consulting, advisory & environmental services, intelligent networks & cybersecurity, design & engineering, procurement, project & construction management, operations & maintenance, decommissioning and capital. The breadth and depth of our capabilities are delivered to clients in strategic sectors such as Engineering Services, Nuclear and Capital. News and information are available at or follow us LinkedIn. About AtkinsRéalis' Nuclear Sector AtkinsRéalis has over 70 years of global nuclear expertise, delivering nuclear technology products and full-service solutions to nuclear utilities around the world. AtkinsRéalis is the steward of CANDU® nuclear technology, operating on four continents, and provides advisory and engineering services to other nuclear developers. With an innovative technology portfolio, including access to over 500 patented solutions, AtkinsRéalis solves technically complex challenges across the whole nuclear lifecycle from design and new build through asset management and from life extension and late life management through decommissioning and waste management. AtkinsRéalis operates and manages government nuclear research sites, transforming ageing infrastructure and safely managing legacy nuclear waste. AtkinsRéalis' CANDU technology also allows for the co-production of medical radioisotopes for cancer detection and treatment. The company also supports cancer treatment through its partnership with TerraPower to extract isotopes from legacy nuclear material. Learn more on our Nuclear market page. Forward-Looking Statements References in this press release to the "Company", "AtkinsRéalis", "we", us" and "our" mean, as the context may require, AtkinsRéalis Group Inc. or all or some of its subsidiaries or joint arrangements or associates. Statements made in this press release that describe the Company's expectations or strategies constitute "forward-looking statements", which can be identified by the use of the conditional or forward-looking terminology such as "estimates", "expects", "forecasts", "intends", "may", "objective", "plans", "projects", "should", "will", "likely", or other variations thereon. Forward-looking statements also include any other statements that do not refer to historical facts. The Company cautions that, by their nature, forward-looking statements involve risks and uncertainties, and that its actual actions or results could differ materially from those expressed or implied in such forward-looking statements. Forward-looking statements are presented for the purpose of assisting investors and others in understanding certain key elements of the Company's current objectives, strategic priorities, expectations and plans, and in obtaining a better understanding of the Company's business and anticipated operating environment. Readers are cautioned that such information may not be appropriate for other purposes. Forward-looking statements made in this press release are based on a number of assumptions believed by the Company to be reasonable as at the date hereof. The assumptions are set out throughout the Company's 2024 annual management disclosure & analysis ("2024 MD&A") (particularly in the sections entitled "Critical Accounting Judgments and Key Sources of Estimation Uncertainty" and "How We Analyze and Report our Results") filed with the securities regulatory authorities in Canada, available on SEDAR+ at and on the Company's website at under the "Investors" section. If these assumptions are inaccurate, the Company's actual results could differ materially from those expressed or implied in such forward-looking statements. In addition, important risk factors could cause the Company's assumptions and estimates to be inaccurate and actual results or events to differ materially from those expressed in or implied by these forward-looking statements. Those risks are identified in the 2024 MD&A (particularly in the section entitled "Risk and Uncertainties"), as may be updated from time to time in the Company's interim quarterly MD&A, are not exhaustive. The forward-looking statements herein reflect the Company's expectations as at the date of this press release and are subject to change after this date. The Company does not undertake to update publicly or to revise any such forward-looking statements whether as a result of new information, future events or otherwise, unless required by applicable legislation or regulation. The forward-looking information and statements contained herein are expressly qualified in their entirety by this cautionary statement. __________________ 1 Source: Ontario Ministry of Energy and Mines, 2 Source: Ontario Ministry of Energy and Mines, SOURCE AtkinsRéalis View original content to download multimedia:
Cision Canada
7 days ago
- Business
- Cision Canada
Laurentis Energy Partners set to produce two powerful cancer-fighting isotopes
With regulatory approval secured, OPG's Darlington reactors will become single largest source of isotope production in North America TORONTO, May 28, 2025 /CNW/ - Cancer patients around the world could soon benefit from improved access to potentially life-saving treatments generated by the production of two critical medical isotopes – Yttrium-90 (Y-90) and Lutetium-177 (Lu-177) – at Ontario Power Generation's (OPG) Darlington Nuclear Generating Station. The Canadian Nuclear Safety Commission has approved a licence amendment that allows OPG subsidiary Laurentis Energy Partners (Laurentis) to begin producing the isotopes in Darlington's CANDU nuclear reactors. These isotopes are part of a new wave of targeted radionuclide therapies that deliver radiation directly to cancer cells while sparing healthy tissue, offering new hope to patients with hard-to-treat cancers such as liver, neuroendocrine, and prostate. Demand for these isotopes is growing rapidly as new treatments are developed and approved in global markets. Darlington's CANDU design enables production of medical isotopes without interrupting electricity generation, ensuring a steady, reliable supply. The isotopes are produced using Laurentis's proprietary isotope irradiation system, developed in partnership with BWXT Medical Ltd. and installed on Unit 2 at Darlington. The system is the single largest isotope production system in North America. When production begins, Darlington will become a key commercial power reactor source of Y-90 and Lu-177 globally. Key facts: This expansion builds on Laurentis's production of Molybdenum-99 at Darlington, the first commercial nuclear station in the world licensed to produce the isotope. Its decay product, Technetium-99m, is used in over 30 million diagnostic procedures annually. In 2024, the first Ontario patient was treated with publicly funded Lu-177-based therapy for prostate cancer. Laurentis could produce enough Lu-177 at Darlington to supply nearly 3 million doses, enough to fully treat 500,000 patients annually and vastly increase the global supply capacity. Once irradiated, Y-90 will be sent to BWXT Medical's facility in Kanata, Ontario, to be packaged into Boston Scientific's TheraSphere® Y-90 Glass Microspheres and distributed to over 30 countries globally. Commercial production of Y-90 is anticipated to begin in 2026, while commercial production of Lu-177 is expected to begin in 2027. Quotes: "For the first time, Ontario will be producing these critical medical isotopes at Darlington's CANDU nuclear reactors. This is leadership as Ontario advances its nuclear advantage, while saving lives for the thousands of Canadians diagnosed with cancer each year," said Stephen Lecce, Ontario's Minister of Energy and Mines. "Protecting Ontario starts with protecting our people. The production of cancer-fighting isotopes at Darlington shows how our world-class nuclear sector is delivering real benefits to people—creating high-skilled jobs, driving innovation, and save lives." "Our government is giving people access to more treatment options by expanding public access to life-saving medications and treatments," said Sylvia Jones, Ontario's Deputy Premier and Minister of Health. "This vital expansion of medical isotope production is another way we are spearheading Ontario-made innovation and connecting more people to world-class cancer care for years to come." "Darlington Nuclear Generating Station is not only helping power Ontario's growing clean energy needs; it is also powering the future of cancer care," said Nicolle Butcher, OPG President and CEO. "The isotopes produced at Darlington will have real-world impact for cancer patients around the world." "For patients and families waiting for new treatment options, this is a moment of real hope," said Jason Van Wart, Laurentis President and CEO. "We're proud to lead Canada's growing role in nuclear medicine, and even prouder to know that our work will directly support life-saving care for patients around the world." About Laurentis Energy Partners Laurentis Energy Partners, a subsidiary of OPG, is a global leader in the production of life-saving medical isotopes. From advanced cancer therapies to diagnostic imaging, Laurentis is helping power the future of nuclear medicine. The company also leverages its access to decades of nuclear knowledge and experience to deliver specialized nuclear services that include small modular reactor development, CANDU refurbishment, inspections, engineering, nuclear byproduct management, and decommissioning support globally. Laurentis has offices in the Greater Toronto Area, Hamilton, and Bruce County in Ontario, Saint John in New Brunswick, Regina in Saskatchewan, and Bucharest and Cernavoda in Romania. Follow us on Twitter/X or LinkedIn or visit
Canada Standard
27-05-2025
- Health
- Canada Standard
Commission amends Ontario Power Generation's operating licence for the Darlington Nuclear Generating Station to authorize the production of lutetium-177 and yttrium-90
May 26 2025 - Ottawa Today, the Canadian Nuclear Safety Commission (CNSC) announced the Commission's decision to amend Ontario Power Generation's (OPG) power reactor operating licence for the Darlington Nuclear Generating Station (NGS) to authorize the production of lutetium-177 (Lu-177) and yttrium-90 (Y-90) using the existing target delivery system on Darlington NGS Unit 2. This decision follows a public hearing in writing with interventions. The amended licence remains valid until November 30, 2025. The Darlington NGS is located in the Municipality of Clarington, Ontario, within the traditional lands and waters of the Michi Saagiig Anishinaabeg, the Gunshot Treaty (1787-88), the Williams Treaties (1923), and the Williams Treaties Settlement Agreement (2018). In making its decision, the Commission considered written submissions from OPG, CNSC staff and 7 intervenors. After reviewing all submissions, the Commission concluded that OPG is qualified to carry on the activities that the amended licence will authorize. The record of decision is available upon request by contacting the Commission Registry at interventions@ It will also be posted in both official languages on the CNSC website at at a later date. All submissions are also available on the CNSC website. The CNSC regulates the use of nuclear energy and materials to protect health, safety, security and the environment; to implement Canada's international commitments on the peaceful use of nuclear energy; and to disseminate objective scientific, technical and regulatory information to the public. The Commission is a quasi-judicial administrative tribunal set up at arm's length from government, independent from any political, government or private sector influence. Quick facts Lu-177 and Y-90 are radioactive isotopes that are used in nuclear medicine, most prominently for targeted radionuclide therapy of certain types of cancer. The Commission is satisfied with the regulatory hold point proposed by CNSC staff to verify aspects of the safety case, including confirmation via commissioning tests, prior to declaring the new isotope production available for service. Related links Contact Media Relations Canadian Nuclear Safety Commission Tel: 613-996-6860 Email: media@
